RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients

Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation Clinical Trial

Official title: RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the effects of a once daily subcutaneous (SC) injection of RM-493, in subjects with POMC (propiomelanocortin) or other related rare genetic mutations, on body weight, metabolic function and blood pressure. Patients who respond during the initial 84 days of treatment can enter into long-term (2-year) extensions. The study drug (RM-493) will be administered in an unblinded fashion.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation

• NCT number: NCT02507492
• Study type: Interventional
• Source: Charite University, Berlin, Germany
• Contact: Susanna Wiegand, PD Dr.
• Phone: +49 30 450 566887
• Email: susanna.wiegand@charite.de
• Status: Recruiting
• Phase: Phase 2
• Start date: January 2015
• Completion date: July 2018